Diabetes Research and Clinical Practice
Volume 61 , Pages S27-S34 , July 2003

Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia

References 

  1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), J. Am. Med. Assoc. 285 (2001) 2486–2497.
  2. Second Joint Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur. Heart J. 1998;19:1434–1503
  3. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diab. Care. 2002;25(Suppl. 1):S50–S60
  4. American Diabetes Association. Diabetes mellitus and exercise. Diab. Care. 2002;25(Suppl. 1):S64–S68
  5. Jung RT. Obesity as a disease. Br. Med. Bull. 1997;53:307–321
  6. Tuomilehto J, Lindström J, Eriksson JG, et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl. J. Med. 2001;344:1343–1350
  7. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl. J. Med. 2002;346:393–403
  8. Laakso M, Lehto S, Penttila I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993;88:1421–1430
  9. Turner RC, Millns H, Neil HAW, et al.  Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br. Med. J. 1998;316:823–828
  10. Isomaa B, Almgren P, Tuomi T, et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab. Care. 2001;24:683–689
  11. Pyörälä K, Pedersen TR, Kjekshus J, Faergemann O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diab. Care. 1997;20:614–620
  12. Sacks FM, Pfeffer MA, Moye LA, et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 1996;335:1001–1009
  13. Sacks FM, Tonkin AM, Shepherd J, et al.  Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation. 2000;102:1893–1900
  14. Haffner SM. Management of dyslipidemia in adults with diabetes. Diab. Care. 1999;21:160–178
  15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  16. Rubins HB, Sander JR, Collins D, et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl. J. Med. 1999;341:410–418
  17. Freeman DJ, Norrie J, Sattar N, et al.  Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357–362
  18. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diab. Care. 2002;25(Suppl. 1):S74–S77
  19. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J. Cardiovasc. Risk. 2001;8:383–390
  20. Davidson M, Ma P, Stein EA, Gotto AJM, et al.  Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am. J. Cardiol. 2002;89:268–275
  21. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am. J. Cardiol. 2003;91:33–41
  22. Durrington P, Hamann A, Tuomilehto J, Smith K, Kallend D. Rosuvastatin alone and in combination with fenofibrate in hyperlipidaemic patients with type 2 diabetes. Diabetelogia. 2001;44(Suppl. 1):A165
  23. Durrington PN, Tuomilehto J, Hamann A, Southworth H, Pears J, Kallend D. Effects of rosuvastatin alone and in combination with fenofibrate on lipid subfractions in patients with type 2 diabetes: results at 24 weeks. Circulation. 2001;104(Suppl. 2):II-177

PII: S0168-8227(03)00125-6

doi: 10.1016/S0168-8227(03)00125-6

Diabetes Research and Clinical Practice
Volume 61 , Pages S27-S34 , July 2003

Article Tools

* Image Usage & Resolution